The influential trade association has said little over the years as health systems, including those of its own trustees, seized patients’ incomes and assets. Now it is reevaluating.
In the wake of a Kaiser Health News investigation, doctors want the University of Virginia’s health system to stop suing its patients over unpaid bills.
Patients were thrilled last month when UVA announced it would scale back lawsuits and provide more financial assistance, but the excitement has waned.
Patients at VCU Health will no longer be taken to court and can more easily get financial assistance to pay their bills.
But critics say the new policy still leaves some patients exposed to lawsuits and crippling bills.
KHN reported this week that the University of Virginia Health System has filed 36,000 lawsuits against patients the past six years.
A Kaiser Health News investigation, which first appeared in The Washington Post, showed that the University of Virginia Health System has sued patients 36,000 times for more than $106 million.
Over six years, the state institution filed 36,000 lawsuits against patients seeking a total of more than $106 million in unpaid bills, a KHN analysis finds.
Congress has a variety of reforms in mind that could roil the drugmaking business and potentially slash prices.
Known as “authorized generics,” in-house spinoffs of brand-name drugs quietly undermine the competition.
In a new poll, consumers give thumbs up to ads that display drug prices and the removal of barriers to generics, among other cost-cutting measures.
The Senate Finance Committee grilled executives from seven major drugmakers on Tuesday.
Tuesday’s Senate Finance Committee hearing could produce fireworks over prices, R&D costs and executive compensation.
Tuesday’s Senate hearing with pharma CEOs will tackle the same issues as the famous Kefauver hearings in 1960.
Sen. Mike Enzi said he knew of a foundation that would import insulin for patients, but it doesn’t appear to exist.
President Donald Trump and FDA officials have pointed to a surge in generic drug approvals, but a data analysis indicates almost half haven’t reached the market.
The White House and HHS want to eliminate a “shadowy system of kickbacks” in the drug industry pipeline.
Patients are often forced into using brand names because drug formularies favor them over cheaper competitors.
Shereese Hickson’s doctor wanted her to try the infusion drug Ocrevus for her multiple sclerosis. Even though Hickson is trained as a medical billing coder, she was shocked to see two doses of the drug priced at $123,019, with her share set at $3,620.
Once viewed as a promising cost-control tool, such insurance faces new competition on benefits menus from more traditional insurance. But, according to new research, none of those choices is getting less expensive.